Fabienne Neulat-Ripoll, Sophie Pasek, Chantal Schenowitz, Carole Dossat, Valérie Barbe, Martin Rottman, Edouard Macheras, Béate Heym, Jean‐Louis Herrmann, Mamadou Daffé, Roland Brosch, Jean‐Loup Risler, Jean‐Louis Gaillard
5 min
Mycobacterium abscessus is a rapidly growing mycobacterium (RGM) that has emerged as a significant, highly antibiotic-resistant pathogen, particularly in patients with cystic fibrosis (CF). Unlike most RGM, which are generally harmless environmental organisms, M. abscessus causes severe, often fatal lung infections. This study sought to elucidate the genetic basis of this unique pathogenicity by sequencing the complete genome of M. abscessus and comparing it to other mycobacterial species.
The researchers performed a whole-genome shotgun sequencing of the M. abscessus type strain (CIP 104536T). They annotated the 5.07 Mb circular chromosome and a 23 kb mercury-resistance plasmid, conducting comparative genomic analyses against the model RGM Mycobacterium smegmatis and other mycobacteria. The team specifically looked for evidence of horizontal gene transfer (HGT) by identifying clusters of genes with atypical sequence content and high similarity to distantly related environmental bacteria, such as actinobacteria and pseudomonads.
The analysis revealed that while M. abscessus possesses core mycobacterial virulence factors, it also harbors a significant number of "non-mycobacterial" genes acquired through horizontal gene transfer. These include genes for phospholipase C, MgtC, and iron transport systems—factors typically associated with intracellular survival and virulence in other pathogens.
Notably, the researchers identified gene clusters involved in the metabolism of aromatic compounds (e.g., phenazine biosynthesis, homogentisate catabolism) that are absent in other sequenced mycobacteria but present in Pseudomonas aeruginosa and Burkholderia cepacia. The presence of these shared metabolic pathways suggests that M. abscessus may occupy similar ecological niches as these other CF-associated pathogens, potentially facilitating its persistence in the lungs of CF patients.
This study provides a genetic explanation for why M. abscessus is uniquely pathogenic among rapidly growing mycobacteria. By identifying specific virulence factors and metabolic pathways acquired from environmental bacteria, the findings suggest that the pathogen's ability to infect humans may be an evolutionary byproduct of its adaptation to complex, competitive environments like biofilms. Furthermore, the overlap in genetic machinery with other CF-associated pathogens raises the possibility of shared mechanisms of infection and persistence, which could inform future therapeutic strategies for managing chronic lung infections in CF patients.
Mycobacterium abscessus is an emerging rapidly growing mycobacterium (RGM) causing a pseudotuberculous lung disease to which patients with cystic fibrosis (CF) are particularly susceptible. We report here its complete genome sequence. The genome of M. abscessus (CIP 104536T) consists of a 5,067,172-bp circular chromosome including 4920 predicted coding sequences (CDS), an 81-kb full-length prophage and 5 IS elements, and a 23-kb mercury resistance plasmid almost identical to pMM23 from Mycobacterium marinum. The chromosome encodes many virulence proteins and virulence protein families absent or present in only small numbers in the model RGM species Mycobacterium smegmatis. Many of these proteins are encoded by genes belonging to a "mycobacterial" gene pool (e.g. PE and PPE proteins, MCE and YrbE proteins, lipoprotein LpqH precursors). However, many others (e.g. phospholipase C, MgtC, MsrA, ABC Fe(3+) transporter) appear to have been horizontally acquired from distantly related environmental bacteria with a high G+C content, mostly actinobacteria (e.g. Rhodococcus sp., Streptomyces sp.) and pseudomonads. We also identified several metabolic regions acquired from actinobacteria and pseudomonads (relating to phenazine biosynthesis, homogentisate catabolism, phenylacetic acid degradation, DNA degradation) not present in the M. smegmatis genome. Many of the "non mycobacterial" factors detected in M. abscessus are also present in two of the pathogens most frequently isolated from CF patients, Pseudomonas aeruginosa and Burkholderia cepacia. This study elucidates the genetic basis of the unique pathogenicity of M. abscessus among RGM, and raises the question of similar mechanisms of pathogenicity shared by unrelated organisms in CF patients.
Sam: So fewer mobile elements means a more reliable scaffold for hosting those acquired clusters. It's not instability — it's the opposite.
Alex: Precisely. It's a high-stakes evolutionary trade-off. The genome is stable enough to reliably maintain those 17 clusters across generations, which is what makes this "Frankenstein" strategy viable long-term rather than just a transient acquisition.
Sam: What's the biggest limitation before we treat these acquired clusters as confirmed virulence drivers?
Alex: The analysis is primarily bioinformatic. Synteny and codon usage are strong signals of horizontal transfer, but they don't tell you whether these genes are expressed during infection, or whether knocking them out would attenuate pathogenicity in a host model. We have the map, but not the functional proof of which roads are actually being used during an active infection.
Sam: So the next step is knockout studies — or at minimum, transcriptomic data from clinical isolates to see which of these clusters are actually active in the CF lung.
Alex: That's one direction. The paper also flags something else worth noting: a mercury resistance plasmid that's nearly identical to one found in M. marinum. That's an unusual finding — it suggests these two species may share overlapping environmental reservoirs, which has implications for understanding where M. abscessus is picking up this foreign DNA in the first place.
Sam: And if you can identify the environmental source, you might be able to trace which pathogenicity islands are present in wild isolates versus clinical ones — and that gap is presumably where the adaptation to the CF lung is happening.
Alex: Exactly. Comparing environmental and clinical isolates systematically could identify the specific acquired elements that distinguish accidental exposure from true clinical adaptation. That's where the next therapeutic targets are most likely to emerge — not in the core mycobacterial genome, but in the borrowed machinery that makes this organism behave like something it evolutionarily isn't.
Sam: It's a genuinely unusual evolutionary story. A rapid grower that's effectively impersonating a slow-growing pathogen by licensing the right tools from its neighbors.
Alex: And the clinical stakes make that story matter. Current treatment regimens for M. abscessus in CF patients are long, toxic, and often fail. Understanding which of these acquired pathways are load-bearing for virulence could finally give us a rational basis for targeting this organism more precisely. Thanks for listening to ResearchPod.